TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07500805: An Exploratory Clinical Study to Evaluate the Safety and Preliminary Efficacy of UCL70805F in the Treatment of Patients With CD70-positive Advanced Renal Clear Cell Carcinoma

Sponsor: UTC Therapeutics Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 21 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07500805 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07500805 Rescue Dossier →